Breaking News
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% Upgrade now
Close

Bristol-Myers Squibb Company (BMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Bristol-Myers Squibb's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
71.71 -0.35    -0.49%
29/09 - Closed. Currency in USD ( Disclaimer )
Pre Market
72.00
+0.29
+0.40%
13:46:15 - Real-time Data
  • Volume: 9,454,536
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 71.16 - 72.61
Type:  Equity
Market:  United States
Bristol-Myers Squibb 71.71 -0.35 -0.49%

Bristol-Myers Squibb Company Company Profile

 
Read the Bristol company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

30250

Equity Type

ORD

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Contact Information

Top Executives

Name Age Since Title
Giovanni Caforio 57 2011 Chairman of the Board & CEO
Theodore Rapp Samuels 67 2017 Lead Independent Director
Gerald L. Storch 65 2012 Independent Director
Paula A. Price 61 2020 Independent Director
Manuel Hidalgo Medina 54 2021 Independent Director
Peter J. Arduini 57 2016 Independent Director
Julia A. Haller 67 2019 Independent Director
Derica W. Rice 57 2020 Independent Director
Phyllis R. Yale 65 2019 Independent Director
Karen H. Vousden 64 2018 Independent Director
Deepak L. Bhatt - 2022 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BMY Comments

Write your thoughts about Bristol-Myers Squibb Company
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ismet Arranjaku
Ismet Arranjaku Oct 06, 2021 16:11
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello
Maxim Latanovschii
Maxim Latanovschii Oct 06, 2021 16:11
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email